Pacgen Life Science Corporation, a life science technology company, focuses on the commercialization of biomedical products and services. It offers lab equipment, such as Fit X1 401, an automated, high-precision pipetting system designed to replace the manual process of PCR/qPCR sample preparation; electronic pipettes; and A + Pipette Controller, an electronic pipette controller designed for use with graduated and volumetric glass and plastic pipets. The company also provides reagent kits. In addition, it develops novel therapeutic drug candidates. Its product candidates include PAC-113, an anti-fungal drug, which has completed a Phase IIb clinical trial for the treatment of oral Candidiasis; and PAC-G31P, a novel peptide therapeutic, which is in preclinical studies for the treatment of inflammatory diseases characterized by non-beneficial neutrophil. The company has license agreement with Demegen, Inc. to expand its exclusive worldwide rights and license to PAC-113 for additional indications, including vaginal, dermatological, and ophthalmic applications. It was formerly known as Pacgen Biopharmaceuticals Corporation and changed its name to Pacgen Life Science Corporation in April 2012. The company was founded in 2004 and is headquartered in Vancouver, Canada.
pacgen life science corp
(PBS:TSX Venture Exchange)
701 West Georgia Street
Vancouver, BC V7Y 1C6
|No competitor information is available for PBS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact PACGEN LIFE SCIENCE CORP, please visit www.pacgenbiopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.